{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T12:32:08Z","timestamp":1792931528660,"version":"4.5.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","psychosomaticsjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychosomatics"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.psym.2017.10.009","type":"journal-article","created":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T20:04:27Z","timestamp":1509739467000},"page":"105-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":190,"title":["QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update"],"prefix":"10.1016","volume":"59","author":[{"given":"Scott R.","family":"Beach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Celano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan M.","family":"Sugrue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Ackerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Noseworthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff C.","family":"Huffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.psym.2017.10.009_bib1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2165\/00002018-200124050-00001","article-title":"Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling","volume":"24","author":"Malik","year":"2001","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.psym.2017.10.009_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.psym.2015.09.003","article-title":"Health Canada warning on citalopram and escitalopram\u2014its effects on prescribing in consultation-liaison psychiatry","volume":"57","author":"Do","year":"2016","journal-title":"Psychosomatics"},{"issue":"9","key":"10.1016\/j.psym.2017.10.009_bib3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1176\/appi.ajp.2016.15111444","article-title":"Outcomes of citalopram dosage risk mitigation in a veteran population","volume":"173","author":"Rector","year":"2016","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.psym.2017.10.009_bib4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/CRD.0b013e31820e8106","article-title":"Depression and cardiac disease: a review","volume":"19","author":"Celano","year":"2011","journal-title":"Cardiol Rev"},{"issue":"12","key":"10.1016\/j.psym.2017.10.009_bib5","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1161\/CIR.0000000000000019","article-title":"Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association","volume":"129","author":"Lichtman","year":"2014","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.psym.2017.10.009_bib6","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.jacc.2006.06.077","article-title":"Only incident depressive episodes after myocardial infarction are associated with new cardiovascular events","volume":"48","author":"de Jonge","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.psym.2017.10.009_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psym.2012.11.001","article-title":"QTc prolongation, torsades de pointes, and psychotropic medications","volume":"54","author":"Beach","year":"2013","journal-title":"Psychosomatics"},{"issue":"11","key":"10.1016\/j.psym.2017.10.009_bib8","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.hrthm.2011.06.024","article-title":"Refining repolarization reserve","volume":"8","author":"Roden","year":"2011","journal-title":"Heart Rhythm"},{"issue":"6","key":"10.1016\/j.psym.2017.10.009_bib9","doi-asserted-by":"crossref","first-page":"23b","DOI":"10.1016\/0002-9149(93)90036-C","article-title":"Measurement of the QT interval and the risk associated with QTc interval prolongation: a review","volume":"72","author":"Moss","year":"1993","journal-title":"Am J Cardiol"},{"issue":"20","key":"10.1016\/j.psym.2017.10.009_bib10","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.psym.2017.10.009_bib11","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1300799","article-title":"Use of azithromycin and death from cardiovascular causes","volume":"368","author":"Svanstrom","year":"2013","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.psym.2017.10.009_bib12","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1001\/jama.2014.4304","article-title":"Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia","volume":"311","author":"Mortensen","year":"2014","journal-title":"J Am Med Assoc"},{"issue":"20","key":"10.1016\/j.psym.2017.10.009_bib13","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.jacc.2015.09.029","article-title":"The Role of macrolide antibiotics in increasing cardiovascular risk","volume":"66","author":"Cheng","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.psym.2017.10.009_bib14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1007\/s00210-016-1286-7","article-title":"Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic","volume":"389","author":"Kang","year":"2016","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.psym.2017.02.013","article-title":"Loperamide abuse and life-threatening arrhythmias: a case report and literature review","volume":"58","author":"Caro","year":"2017","journal-title":"Psychosomatics"},{"issue":"1","key":"10.1016\/j.psym.2017.10.009_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jelectrocard.2004.09.001","article-title":"Drug-induced QT dispersion: does it predict the risk of torsade de pointes?","volume":"38","author":"Shah","year":"2005","journal-title":"J Electrocardiol"},{"issue":"6","key":"10.1016\/j.psym.2017.10.009_bib17","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1042\/CS20030010","article-title":"T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity","volume":"105","author":"Yamaguchi","year":"2003","journal-title":"Clin Sci"},{"issue":"2","key":"10.1016\/j.psym.2017.10.009_bib18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0008-6363(01)00263-2","article-title":"Non-invasive testing of acquired long QT syndrome: evidence for multiple arrhythmogenic substrates","volume":"50","author":"Chevalier","year":"2001","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.psym.2017.10.009_bib19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10557-015-6619-0","article-title":"Electrocardiographic predictors of torsadogenic risk during dofetilide or sotalol initiation: utility of a novel T wave analysis program","volume":"29","author":"Sugrue","year":"2015","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"10.1016\/j.psym.2017.10.009_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.7205\/MILMED.170.5.381","article-title":"Bradycardia-associated torsade de pointes and the long-QT syndromes: a case report and review of the literature","volume":"170","author":"Ashworth","year":"2005","journal-title":"Mil Med"},{"key":"10.1016\/j.psym.2017.10.009_bib21","series-title":"Cardiovascular Medicine","first-page":"2039","article-title":"Sudden cardiac death","author":"Rasekh","year":"2007"},{"issue":"3","key":"10.1016\/j.psym.2017.10.009_bib22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ancard.2010.12.002","article-title":"Torsade de pointes induced by citalopram and amiodarone","volume":"60","author":"Fayssoil","year":"2011","journal-title":"Ann Cardiol Angeiol"},{"issue":"11","key":"10.1016\/j.psym.2017.10.009_bib23","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2008.12.014","volume":"53","author":"Rautaharju","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.psym.2017.10.009_bib24","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/heart.87.3.220","article-title":"Relation between QT and RR intervals is highly individual among healthy subjects: implications for heart rate correction of the QT interval","volume":"87","author":"Malik","year":"2002","journal-title":"Heart"},{"issue":"9","key":"10.1016\/j.psym.2017.10.009_bib25","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/j.1540-8159.1999.tb00635.x","article-title":"Comparison of formulae for heart rate correction of QT interval in exercise electrocardiograms","volume":"22","author":"Aytemir","year":"1999","journal-title":"Pacing Clin Electrophysiol"},{"issue":"9","key":"10.1016\/j.psym.2017.10.009_bib26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.hrthm.2006.05.023","article-title":"Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval","volume":"3","author":"Indik","year":"2006","journal-title":"Heart Rhythm"},{"issue":"8","key":"10.1016\/j.psym.2017.10.009_bib27","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1540-8167.2010.01738.x","article-title":"Preferred QT correction formula for the assessment of drug-induced QT interval prolongation","volume":"21","author":"Chiladakis","year":"2010","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"6","key":"10.1016\/j.psym.2017.10.009_bib28","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003264","article-title":"Which QT correction formulae to use for QT monitoring?","volume":"5","author":"Vandenberk","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib29","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jpeds.2014.12.037","article-title":"Comparison of formulas for calculation of the corrected QT interval in infants and young children","volume":"166","author":"Phan","year":"2015","journal-title":"J Pediatr."},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib30","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.mayocp.2013.01.013","article-title":"Institution-wide QT alert system identifies patients with a high risk of mortality","volume":"88","author":"Haugaa","year":"2013","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","article-title":"Development and validation of a risk score to predict QT interval prolongation in hospitalized patients","volume":"6","author":"Tisdale","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"2","key":"10.1016\/j.psym.2017.10.009_bib32","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s11096-017-0446-2","article-title":"Development of a risk score for QTc-prolongation: the RISQ-PATH study","volume":"39","author":"Vandael","year":"2017","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.psym.2017.10.009_bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jelectrocard.2014.10.005","article-title":"QTC intervals can be assessed with the AliveCor heart monitor in patients on dofetilide for atrial fibrillation","volume":"48","author":"Chung","year":"2015","journal-title":"J Electrocardiol"},{"issue":"10","key":"10.1016\/j.psym.2017.10.009_bib34","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1161\/CIRCULATIONAHA.108.191096","volume":"119","author":"Rautaharju","year":"2009","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.psym.2017.10.009_bib35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0022-0736(90)90150-Z","article-title":"QT interval and repolarization time in patients with intraventricular conduction delay","volume":"23","author":"Das","year":"1990","journal-title":"J Electrocardiol"},{"issue":"Suppl","key":"10.1016\/j.psym.2017.10.009_bib36","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0022-0736(92)90079-F","article-title":"Should the JT rather than the QT interval be used to detect prolongation of ventricular repolarization? An assessment in normal conduction and in ventricular conduction defects","volume":"25","author":"Zhou","year":"1992","journal-title":"J Electrocardiol"},{"issue":"9","key":"10.1016\/j.psym.2017.10.009_bib37","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/appi.ajp.2011.10121734","article-title":"Safety of antipsychotics in the setting of QTc prolongation: the utility of the JT index","volume":"168","author":"Mukherji","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.psym.2017.10.009_bib38","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.psym.2013.02.007","article-title":"Consideration of the JT interval rather than the QT interval","volume":"54","author":"Salik","year":"2013","journal-title":"Psychosomatics"},{"issue":"8","key":"10.1016\/j.psym.2017.10.009_bib39","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.amjcard.2003.12.055","article-title":"Assessment of prolonged QT and JT intervals in ventricular conduction defects","volume":"93","author":"Rautaharju","year":"2004","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.psym.2017.10.009_bib40","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.hrthm.2014.08.026","article-title":"New formula for evaluation of the QT interval in patients with left bundle branch block","volume":"11","author":"Bogossian","year":"2014","journal-title":"Heart Rhythm"},{"issue":"9","key":"10.1016\/j.psym.2017.10.009_bib41","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.amjcard.2013.06.027","article-title":"Correlation of QT interval correction methods during atrial fibrillation and sinus rhythm","volume":"112","author":"Musat","year":"2013","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.psym.2017.10.009_bib42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.psym.2013.02.011","article-title":"Protected from torsades de pointes? What psychiatrists need to know about pacemakers and defibrillators","volume":"54","author":"Brojmohun","year":"2013","journal-title":"Psychosomatics"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib43","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00228-012-1408-1","article-title":"Citalopram and cardiac toxicity","volume":"69","author":"Cooke","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.psym.2017.10.009_bib44","first-page":"139","article-title":"The effectiveness and limitations of regulatory warnings for the safe prescribing of citalopram","volume":"7","author":"Friesen","year":"2015","journal-title":"Drug Healthc Patient Saf"},{"key":"10.1016\/j.psym.2017.10.009_bib45","doi-asserted-by":"crossref","first-page":"f288","DOI":"10.1136\/bmj.f288","article-title":"QT interval and antidepressant use: a cross sectional study of electronic health records","volume":"346","author":"Castro","year":"2013","journal-title":"Br Med J"},{"issue":"5","key":"10.1016\/j.psym.2017.10.009_bib46","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.4088\/JCP.13r08672","article-title":"Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation","volume":"75","author":"Beach","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.psym.2017.10.009_bib47","doi-asserted-by":"crossref","first-page":"e98426","DOI":"10.1371\/journal.pone.0098426","article-title":"Changes in QTc interval in the citalopram for agitation in Alzheimer\u2032s disease (CitAD) randomized trial","volume":"9","author":"Drye","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.psym.2017.10.009_bib48","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1176\/appi.ajp.2013.12060860","article-title":"Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study","volume":"170","author":"Girardin","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib49","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/bcp.12681","article-title":"Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study","volume":"80","author":"Maljuric","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.psym.2017.10.009_bib50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.psym.2014.09.002","article-title":"Citalopram, QTc Prolongation, and Torsades de Pointes","volume":"56","author":"Tampi","year":"2015","journal-title":"Psychosomatics"},{"issue":"6","key":"10.1016\/j.psym.2017.10.009_bib51","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1176\/appi.ajp.2013.12030408","article-title":"Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40mg","volume":"170","author":"Zivin","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.psym.2017.10.009_bib52","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4088\/JCP.15m10324","article-title":"High-dose citalopram and escitalopram and the risk of out-of-hospital death","volume":"78","author":"Ray","year":"2017","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.psym.2017.10.009_bib53","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.amjmed.2011.12.002","article-title":"Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?","volume":"125","author":"Vieweg","year":"2012","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"10.1016\/j.psym.2017.10.009_bib54","first-page":"226","article-title":"The impact of guidance on citalopram\u2032s effects on the QT period on the practice of clinicians","volume":"26","author":"Austin","year":"2014","journal-title":"Psychiatr Danub"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib55","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jagp.2016.11.010","article-title":"Unintended consequences of adjusting citalopram prescriptions following the 2011 FDA warning","volume":"25","author":"Gerlach","year":"2017","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib56","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/jpn.130055","article-title":"Escitalopram and QTc prolongation","volume":"38","author":"Hasnain","year":"2013","journal-title":"J Psychiatry Neurosci"},{"issue":"9","key":"10.1016\/j.psym.2017.10.009_bib57","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/PEC.0b013e3182a314b7","article-title":"Sodium channel blockade with QRS widening after an escitalopram overdose","volume":"29","author":"Schreffler","year":"2013","journal-title":"Pediatr Emerg Care"},{"issue":"11","key":"10.1016\/j.psym.2017.10.009_bib58","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.euroneuro.2013.05.011","article-title":"The cardiovascular safety profile of escitalopram","volume":"23","author":"Thase","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib59","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu080","article-title":"Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010","volume":"18","author":"Spindelegger","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.psym.2017.10.009_bib60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.13m08397","article-title":"QT interval prolongation in users of selective serotonin reuptake inhibitors in an elderly surgical population: a cross-sectional study","volume":"75","author":"van Haelst","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.psym.2017.10.009_bib61","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/DBP.0000000000000188","article-title":"A systematic evaluation of the QTc interval and antidepressants in youth: an electronic health record study","volume":"36","author":"Uchida","year":"2015","journal-title":"J Dev Behav Pediatr"},{"issue":"5","key":"10.1016\/j.psym.2017.10.009_bib62","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1089\/cap.2008.0136","article-title":"Observation of QTc prolongation in an adolescent girl during fluvoxamine pharmacotherapy","volume":"19","author":"Brzozowska","year":"2009","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"10.1016\/j.psym.2017.10.009_bib63","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1345\/aph.1E513","article-title":"QTc prolongation associated with combination therapy of levofloxacin, imipramine, and fluoxetine","volume":"39","author":"Nykamp","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"12","key":"10.1016\/j.psym.2017.10.009_bib64","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1177\/1060028014550645","article-title":"Risk of QT\/QTc prolongation among newer non-SSRI antidepressants","volume":"48","author":"Jasiak","year":"2014","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.psym.2017.10.009_bib65","first-page":"1","article-title":"Desvenlafaxine overdose and the occurrence of serotonin toxicity, seizures and cardiovascular effects","author":"Cooper","year":"2016","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.psym.2017.10.009_bib66","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.2147\/NDT.S114955","article-title":"Efficacy and safety of multiple doses of levomilnacipran extended-release for the treatment of major depressive disorder","volume":"12","author":"Huang","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib67","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1111\/bcp.12829","article-title":"Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults\u2014a Swedish nationwide study","volume":"81","author":"Danielsson","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.psym.2017.10.009_bib68","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/15563650.2013.859264","article-title":"Mirtazapine overdose is unlikely to cause major toxicity","volume":"52","author":"Berling","year":"2014","journal-title":"Clin Toxicol"},{"issue":"9","key":"10.1016\/j.psym.2017.10.009_bib69","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/pds.2181","article-title":"Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia","volume":"20","author":"Leonard","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib70","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/cpdd.51","article-title":"Effect of vortioxetine on cardiac repolarization in healthy adult male subjects: results of a thorough QT\/QTc study","volume":"2","author":"Wang","year":"2013","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"10.1016\/j.psym.2017.10.009_bib71","doi-asserted-by":"crossref","first-page":"456","DOI":"10.5414\/CP201826","article-title":"Vilazodone lacks proarrhythmogenic potential in healthy participants: a thorough ECG study","volume":"51","author":"Edwards","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.psym.2017.10.009_bib72","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FJC.0000000000000136","article-title":"Evaluation of the effects of therapeutic and supratherapeutic doses of agomelatine on the QT\/QTc interval: a phase I, randomized, double-blind, placebo-controlled and positive-controlled, crossover thorough QT\/QTc study conducted in healthy volunteers","volume":"64","author":"Donazzolo","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"issue":"9","key":"10.1016\/j.psym.2017.10.009_bib73","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/ijcp.12714","volume":"69","author":"Citrome","year":"2015","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.psym.2017.10.009_bib74","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/JCP.0000000000000321","article-title":"Assessing prolongation of the heart rate corrected QT interval in users of tricyclic antidepressants: advice to use fridericia rather than bazett\u2032s correction","volume":"35","author":"Noordam","year":"2015","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib75","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/hup.2540","article-title":"First-generation antipsychotics and QTc: any role for mediating variables?","volume":"31","author":"Carra","year":"2016","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"10.1016\/j.psym.2017.10.009_bib76","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ajem.2014.09.048","article-title":"Risk factors for QT prolongation associated with acute psychotropic drug overdose","volume":"33","author":"Miura","year":"2015","journal-title":"Am J Emerg Med"},{"issue":"2","key":"10.1016\/j.psym.2017.10.009_bib77","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001568","article-title":"Antipsychotic drugs and the risk of ventricular arrhythmia and\/or sudden cardiac death: a nation-wide case-crossover study","volume":"4","author":"Wu","year":"2015","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib78","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bcp.12527","article-title":"Small doses of droperidol do not present relevant torsadogenic actions: a double-blind, ondansetron-controlled study","volume":"79","author":"Tracz","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.psym.2017.10.009_bib79","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.annemergmed.2015.03.016","article-title":"The safety and effectiveness of droperidol for sedation of acute behavioral disturbance in the emergency department","volume":"66","author":"Calver","year":"2015","journal-title":"Ann Emerg Med"},{"issue":"5","key":"10.1016\/j.psym.2017.10.009_bib80","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/bcp.12272","article-title":"High dose droperidol and QT prolongation: analysis of continuous 12-lead recordings","volume":"77","author":"Calver","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.psym.2017.10.009_bib81","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/ALN.0b013e31827dde8d","article-title":"Does low-dose droperidol increase the risk of polymorphic ventricular tachycardia or death in the surgical patient?","volume":"118","author":"Nuttall","year":"2013","journal-title":"Anesthesiology"},{"issue":"6","key":"10.1016\/j.psym.2017.10.009_bib82","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/jcph.257","article-title":"Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT\/QTc study in healthy subjects","volume":"54","author":"Spyker","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.psym.2017.10.009_bib83","doi-asserted-by":"crossref","first-page":"963","DOI":"10.5414\/CP202457","article-title":"A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers","volume":"53","author":"Cassella","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"9896","key":"10.1016\/j.psym.2017.10.009_bib84","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.psym.2017.10.009_bib85","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/hup.2458","article-title":"QTc prolongation in schizophrenia patients in Asia: clinical correlates and trends between 2004 and 2008\/2009","volume":"30","author":"Xiang","year":"2015","journal-title":"Hum Psychopharmacol"},{"issue":"6","key":"10.1016\/j.psym.2017.10.009_bib86","first-page":"1","article-title":"Antipsychotics and the Risks of Sudden Cardiac Death and All-Cause Death: Cohort Studies in Medicaid and Dually-Eligible Medicaid-Medicare Beneficiaries of Five States","volume":"10","author":"Leonard","year":"2013","journal-title":"J Clin Exp Cardiolog"},{"issue":"11","key":"10.1016\/j.psym.2017.10.009_bib87","doi-asserted-by":"crossref","first-page":"e81208","DOI":"10.1371\/journal.pone.0081208","article-title":"Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe","volume":"8","author":"Raschi","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.psym.2017.10.009_bib88","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.pnpbp.2010.01.008","article-title":"QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia","volume":"34","author":"Ozeki","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"10.1016\/j.psym.2017.10.009_bib89","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.psym.2014.07.004","article-title":"QTc prolongation and haloperidol: just how risky is this drug?","volume":"55","author":"Howland","year":"2014","journal-title":"Psychosomatics"},{"issue":"7","key":"10.1016\/j.psym.2017.10.009_bib90","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2165\/11599960-000000000-00000","article-title":"Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol","volume":"35","author":"Muzyk","year":"2012","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.psym.2017.10.009_bib91","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11096-015-0242-9","article-title":"Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium","volume":"38","author":"Vandael","year":"2016","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"10.1016\/j.psym.2017.10.009_bib92","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bcp.12040","article-title":"Drug induced QT prolongation: the measurement and assessment of the QT interval in clinical practice","volume":"76","author":"Isbister","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.psym.2017.10.009_bib93","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.annemergmed.2014.12.005","article-title":"Prolonged QT risk assessment in antipsychotic overdose using the QT nomogram","volume":"66","author":"Berling","year":"2015","journal-title":"Ann Emerg Med"},{"issue":"18","key":"10.1016\/j.psym.2017.10.009_bib94","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1007\/s00213-015-4024-9","article-title":"The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach","volume":"232","author":"Polcwiartek","year":"2015","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.psym.2017.10.009_bib95","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/JCP.0000000000000577","article-title":"Evaluation of the relationship between pharmacokinetics and the safety of aripiprazole and its cardiovascular effects in healthy volunteers","volume":"36","author":"Belmonte","year":"2016","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.psym.2017.10.009_bib96","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/JCP.0000000000000213","article-title":"Aripiprazole-associated QTc prolongation in a geriatric patient","volume":"34","author":"Hategan","year":"2014","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.psym.2017.10.009_bib97","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1345\/aph.1R387","article-title":"Torsades de pointes after administration of low-dose aripiprazole","volume":"47","author":"Nelson","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.psym.2017.10.009_bib98","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JCP.0b013e31827c0314","article-title":"A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and\/or CYP3A4 and a comparison to quetiapine and ziprasidone","volume":"33","author":"Potkin","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib99","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/JCP.0b013e3182977308","article-title":"High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study","volume":"33","author":"Goff","year":"2013","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib100","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/11599010-000000000-00000","article-title":"Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data","volume":"26","author":"Camm","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psym.2017.10.009_bib101","first-page":"489493","article-title":"QT interval prolongation associated with intramuscular ziprasidone in chinese patients: a case report and a comprehensive literature review with meta-analysis","volume":"2014","author":"Li","year":"2014","journal-title":"Case Rep Psychiatry"},{"issue":"10","key":"10.1016\/j.psym.2017.10.009_bib102","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s40263-014-0196-9","article-title":"QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review","volume":"28","author":"Hasnain","year":"2014","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib103","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00213-013-3192-8","article-title":"Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports","volume":"228","author":"Vieweg","year":"2013","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib104","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/YIC.0000000000000124","article-title":"A thorough QT study to evaluate the QTc prolongation potential of two neuropsychiatric drugs, quetiapine and escitalopram, in healthy volunteers","volume":"31","author":"Kim","year":"2016","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.psym.2017.10.009_bib105","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.euroneuro.2014.12.005","article-title":"Cardiac effects of sertindole and quetiapine: analysis of ECGs from a randomized double-blind study in patients with schizophrenia","volume":"25","author":"Nielsen","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"10.1016\/j.psym.2017.10.009_bib106","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/2045125313510194","article-title":"Quetiapine, QTc interval prolongation, and torsade de pointes: a review of case reports","volume":"4","author":"Hasnain","year":"2014","journal-title":"Ther Adv Psychopharmacol"},{"issue":"6","key":"10.1016\/j.psym.2017.10.009_bib107","first-page":"326","article-title":"The efficacy and safety of 12 weeks of treatment with sertindole or olanzapine in patients with chronic schizophrenia who did not respond successfully to their previous treatments: a randomized, double-blind, parallel-group, flexible-dose study","volume":"27","author":"Kwon","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"10.1016\/j.psym.2017.10.009_bib108","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/pcn.12136","article-title":"Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia","volume":"68","author":"Suzuki","year":"2014","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.psym.2017.10.009_bib109","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/15563650.2013.862258","article-title":"Adverse effects associated with high-dose olanzapine therapy in patients admitted to inpatient psychiatric care","volume":"52","author":"Petersen","year":"2014","journal-title":"Clin Toxicol"},{"key":"10.1016\/j.psym.2017.10.009_bib110","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jpsychires.2015.07.005","article-title":"Intramuscular olanzapine for agitated patients: A systematic review and meta-analysis of randomized controlled trials","volume":"68","author":"Kishi","year":"2015","journal-title":"J Psychiatr Res"},{"issue":"5","key":"10.1016\/j.psym.2017.10.009_bib111","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/070674371506000503","article-title":"Antipsychotic polypharmacy and corrected QT interval: a systematic review","volume":"60","author":"Takeuchi","year":"2015","journal-title":"Can J Psychiatry"},{"issue":"2","key":"10.1016\/j.psym.2017.10.009_bib112","doi-asserted-by":"crossref","first-page":"e0148212","DOI":"10.1371\/journal.pone.0148212","article-title":"Antipsychotic dose mediates the association between polypharmacy and corrected QT interval","volume":"11","author":"Barbui","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.psym.2017.10.009_bib113","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/00002018-200326100-00006","article-title":"Cardiovascular effects of atomoxetine in children, adolescents, and adults","volume":"26","author":"Wernicke","year":"2003","journal-title":"Drug Saf"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib114","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1176\/appi.ajp.161.4.757","article-title":"Seizures and prolonged QTc with atomoxetine overdose","volume":"161","author":"Sawant","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"12","key":"10.1016\/j.psym.2017.10.009_bib115","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1007\/s00431-013-2206-1","article-title":"Life-threatening QT prolongation in a boy with attention-deficit\/hyperactivity disorder on atomoxetine","volume":"173","author":"Yamaguchi","year":"2014","journal-title":"Eur J Pediatr"},{"issue":"4","key":"10.1016\/j.psym.2017.10.009_bib116","doi-asserted-by":"crossref","first-page":"372","DOI":"10.5664\/jcsm.27550","article-title":"Unsuccessful suicide attempt of a 15 year old adolescent with ingestion of 5000mg modafinil","volume":"5","author":"Neuman","year":"2009","journal-title":"J Clin Sleep Med"},{"issue":"1","key":"10.1016\/j.psym.2017.10.009_bib117","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40263-012-0019-9","article-title":"Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder","volume":"27","author":"Martinez-Raga","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.psym.2017.10.009_bib118","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2015-211900","article-title":"A case of donepezil-related torsades de pointes","volume":"2015","author":"Kitt","year":"2015","journal-title":"BMJ Case Rep"},{"issue":"6","key":"10.1016\/j.psym.2017.10.009_bib119","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40264-014-0161-z","article-title":"Cardiovascular effects of drugs used to treat Alzheimer\u2032s disease","volume":"37","author":"Howes","year":"2014","journal-title":"Drug Saf"},{"issue":"12","key":"10.1016\/j.psym.2017.10.009_bib120","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.clinthera.2013.10.011","article-title":"Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT\/QTc study in healthy adults","volume":"35","author":"Davy","year":"2013","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.psym.2017.10.009_bib121","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/qjmed\/hcs176","article-title":"Oxycodone overdose causes naloxone responsive coma and QT prolongation","volume":"106","author":"Berling","year":"2013","journal-title":"Qjm"},{"key":"10.1016\/j.psym.2017.10.009_bib122","unstructured":"Arizona Center for Education and Research on Therapeutics. CredibleMeds [August 29, 2017]. Available from: https:\/\/crediblemeds.org\/"},{"issue":"11","key":"10.1016\/j.psym.2017.10.009_bib123","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.mayocp.2012.07.009","article-title":"Considerations on safety concerns about citalopram prescribing","volume":"87","author":"Sheeler","year":"2012","journal-title":"Mayo Clin Proc"}],"container-title":["Psychosomatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318217302207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033318217302207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T17:22:59Z","timestamp":1750958579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033318217302207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":123,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0033318217302207"],"URL":"https:\/\/doi.org\/10.1016\/j.psym.2017.10.009","relation":{},"ISSN":["0033-3182"],"issn-type":[{"value":"0033-3182","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update","name":"articletitle","label":"Article Title"},{"value":"Psychosomatics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psym.2017.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Academy of Psychosomatic Medicine. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}